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Cortistatin (CST)-14, a neuropeptide with high homology with
somatostatin (SS)-14, binds all sst subtypes but, unlike SS, also
ghrelin’s receptor. In six normal adults, we studied the effects
of CST-14 or SS-14 administration (2.0g/kg/h iv) on: 1) GH and
insulin secretion; 2) the GH response to GHRH (1.0 g/kg iv);
and 3) the GH, prolactin (PRL), ACTH, cortisol, insulin, and
glucose responses to ghrelin (1.0 g/kg iv). CST-14 inhibited
GH and insulin secretion (P < 0.01) to the same extent of SS-14.
The GH response to GHRH was similarly inhibited (P < 0.01)
by either CST-14 or SS-14. Ghrelin released more GH than
GHRH (P < 0.01); these responses were similarly inhibited
(P < 0.05) by either CST-14 or SS-14, that made ghrelin-
induced GH rise similar to that after GHRH alone. Neither
CST-14 nor SS-14 modified PRL, ACTH, or cortisol responses
to ghrelin. The inhibitory effect of CST-14 and SS-14 on insulin
was unaffected by ghrelin that, in turn, reduced insulin se-
cretion per se (P < 0.01). Ghrelin increased glucose levels (P <
0.05); CST-14 and SS-14 did not modify this effect. Thus, CST-14
inhibits both basal and stimulated GH secretion in humans to
the same extent of SS-14. The GH-releasing activity of ghrelin
seems partially resistant to CST-14 as well as SS-14. CST-14
and SS-14 do not affect PRL and ACTH secretion but, like
ghrelin, inhibit insulin secretion; the ghrelin-induced inhibi-
tion is not additive with that of CST-14 or SS-14, suggesting a
common mechanism of action on  cell secretion. (J Clin En-
docrinol Metab 87: 3783–3790, 2002)
CORTISTATIN (CST) IS a recently described neuropep-tide, the prepropeptide cDNA of which has been
cloned from rat (1, 2) and more recently from mouse and
human (1, 3, 4). Prepro-CST shows high structural homology
with preprosomatostatin (-SS), particularly in the carboxyl
terminus from which SS-14 and SS–28 are enzymatically
processed (1, 3). Interestingly, rat prepro-CST may also be
cleaved to pro-CST from which the two mature products
CST-14 and CST-29 can be generated in rat (1, 2) and CST-17
and CST-29 in human (1, 3, 4). CST-14 shares 11 of the 14
amino acid residues with SS-14, although these peptides are
encoded by distinct genes (1, 2).
SS exerts its biological effects via membrane-bound recep-
tors of which five subtypes (sst 1 through sst 5) have been
cloned (5, 6). SS receptors are expressed in the brain and
periphery (5, 6) and mediate multiple SS activities including
neurotransmission, neuromodulation, regulation of endo-
crine, and exocrine secretions and also the inhibition of tu-
mor growth (5, 6).
CST-14, as well as CST-17 and -29, binds to all SS re-
ceptor subtypes with an affinity (1–2 nm) close to that of
SS-14 and, therefore, was expected to have similar bio-
logical activities (1, 3, 7). The existence of specific receptors
that selectively bind SS or CST has been hypothesized (1,
7), and indeed CST possesses central activities that are not
shared by SS (1, 8, 9). For instance, CST, unlike SS, reduces
locomotor activity and induces slow-wave sleep (1, 2), and
CST and SS are often coexpressed in the same neurons but
are regulated by different stimuli (1, 10, 11). Moreover, it
has been recently demonstrated that in human tissues
CST-14 as well as CST-17 but not SS-14 bind the GH secre-
tagogue receptor (GHS-R) (Refs. 12 and 13; our unpub-
lished results), an endogenous ligand, which includes gh-
relin, a gastric peptide playing a major role in the control
of somatotroph secretion (14, 15). Evidence that CST to-
tally displaces the binding of iodinated ghrelin from its
receptor would predict that CST but not SS has some
interaction with ghrelin receptor and activity (12, 13).
Besides GHRH and SS receptors (16, 17), the GHS-R has
been postulated to mediate a major stimulatory role in the
control of GH secretion as well (18–20). GHS-R had been
cloned following the evidence that synthetic peptidyl and
nonpeptidyl molecules, named GHSs, show strong GH-
releasing activity acting at the pituitary and mainly at the
hypothalamic levels in which specific receptors are present
(18–21). GHS-Rs are, however, present also in extrahypo-
thalamic brain areas and peripheral animal and human tis-
sues in which they mediate GH-independent activities in-
cluding orexigenic and metabolic actions (18–25).
Ghrelin is a 28-amino acid peptide with an n-octanoyl ester
in the serine 3 that is essential for its potent GH-releasing
activity (14, 15). Ghrelin is mostly synthesized in the stom-
ach, but it is also expressed in several other tissues including
the hypothalamic arcuate nucleus (14, 15). Regarding GH
secretion, ghrelin has no interaction with synthetic GHSs but
shows synergic effect with GHRH and partial refractoriness
to the inhibitory effect of exogenous SS (26–28). The activity
Abbreviations: CST, Cortistatin; GHS-R, GH secretagogue receptor;
PRL, prolactin; SS, somatostatin.
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of ghrelin is not fully specific for GH, being able to stimulate
also lactotroph and corticotroph secretion (26, 29) as well as
to exert central and peripheral actions including influence on
insulin secretion and glucose metabolism (30–32).
The endocrine activities of CST in humans have never been
investigated so far, and to address this point, we studied the
effects of CST-14 in comparison with those of SS-14 on basal
GH and insulin secretion; the GH responses to GHRH; and
the GH, prolactin (PRL), ACTH, cortisol, insulin, and glucose
responses to ghrelin in normal young volunteers.
Given the ability of CST-14 but not SS-14 to bind the
GHS-R, this study was also willing to verify whether CST-14
had some peculiar interaction with ghrelin or the activation
of all SS receptor subtypes by CST-14 as well as by SS-14 leads
to the same endocrine effects.
Subjects and Methods
Six healthy young male volunteers [age (mean  sem): 28.7  2.9 yr;
body mass index: 23.4  0.8 kg/m2] were studied.
All subjects gave their written informed consent to participate in the
study, which had been approved by an independent ethical committee.
All subjects underwent the following nine testing sessions in random
order at least 3 d apart: 1) saline; 2) CST-14 [Pro-c(Cys-Lys-Asn-Phe-
Phe-Trp-Lys-Thr-Phe-Ser-Ser-Cys)-Lys-NH2, Europeptides, Argenteuil,
France; 2.0 g/kg iv over 120 min from 30 to 90 min]; 3) SS-14
[Ala-Gly-c(Cys-Lys-Asn-Phe-Phe-Trp-Lys-Thr-Phe-Thr-Ser-Cys)-OH,
Serono, Geneva, Switzerland; 2.0 g/kg iv over 120 min from 30 to
90 min]; 4) GHRH-29 (Serono, 1.0 g/kg iv at 0 min); 5) Ghrelin-28
(Europeptides, 1.0 g/kg iv at 0 min); 6) GHRH CST; 7) GHRH SS;
8) Ghrelin  CST; 9) Ghrelin  SS.
After an overnight fast, testing sessions began in the morning at
0830–0900 h, 30 min after an indwelling catheter had been placed into
an antecubital vein of the forearm kept patent by slow infusion of
isotonic saline. None of the subjects were under treatment with any
drug. Smoking and alcohol consumption were not allowed in the 12 h
preceding the testing sessions.
Blood samples were taken every 15 min from30 up to90 min. GH
levels were assayed at each time point in all sessions. Insulin and glucose
levels were assayed during CST and SS infusions both alone and in
combination with ghrelin. PRL, ACTH, and cortisol levels were assayed
after ghrelin administration both alone and during CST or SS infusion.
Serum GH levels (micrograms per liter; 1 g/liter 45.4 pmol/liter)
were measured in duplicate by immunoradiometric assay (hGH-CTK
IRMA, SORIN Biomedica, Saluggia, Italy). The sensitivity of the assay
was 0.15g/liter. The inter- and intraassay coefficients of variation were
2.9–4.5% and 2.4–4.0%, respectively.
Serum PRL levels (micrograms per liter; 1 g/liter 43.5 pmol/liter)
were measured in duplicate by immunoradiometric assay (PRL-CTK,
IRMA, SORIN Biomedica). The sensitivity of the assay was 0.5 g/liter.
The inter- and intraassay coefficients of variation ranged from 3.9% to
6.8% and from 3.3% to 7.5%, respectively.
Plasma ACTH levels (picograms per milliliter; 1 pg/ml  0.2202
pmol/liter) were measured by immunoradiometric assay (ACTH, Ni-
chols Institute Diagnostic, San Juan Capistrano, CA). The sensitivity of
the assay was 1 pg/ml. The ranges of inter- and intraassay coefficients
of variation were 2.4–8.5% and 3.9–9.9%, respectively.
Serum cortisol levels (micrograms per liter; 1 g/liter 2.759 nmol/
liter) were measured in duplicate by RIA (CORT-CTK 125, IRMA,
SORIN Biomedica). The sensitivity of the assay was 4.0 g/liter. The
inter- and intraassay coefficients of variation ranged from 6.6–7.5% and
from 3.8–6.6%, respectively.
Serum insulin levels (milliunits per liter; 1 mU/liter  7.175 pmol/
liter) were measured in duplicate by immunoradiometric assay (IN-
SIK-5, SORIN Biomedica). The sensitivity of the assay was 2.5  0.3
mU/liter. The inter- and intraassay coefficients of variation were 6.2–
10.8% and 5.5–10.6%, respectively.
Plasma glucose levels (milligrams per deciliter; 1 mg/dl  0.05551
mmol/liter) were measured by glucooxidase colorimetric method
(GLUCOFIX, Menarini Diagnostici, Florence, Italy).
All samples from an individual subject were analyzed together.
The hormonal responses are expressed as absolute and delta areas
under curves calculated by trapezoidal integration.
The statistical analysis was carried out using nonparametric ANOVA
(Friedman test) and then Wilcoxon test, as appropriate.
The results are expressed as mean  sem.
Results
CST inhibited basal GH secretion (delta area under the
curve:126.6 96.3 vs. 6.0 2.5 g/liter/h, P 0.01) to the
same extent of SS (151.5  132.0 g/liter/h, P  0.01)
(Fig. 1).
The GH response to GHRH was inhibited (P  0.01) by
either CST or SS to the same extent (Table 1 and Fig. 2). The
percentage inhibitory effects of CST and SS on the mean GH
responses to GHRH were similar (79% and 86%,
respectively).
Ghrelin induced GH increase that was markedly higher
(P  0.01) than that elicited by GHRH. (Tables 1 and 2 and
Fig. 2). CST and SS inhibited to the same extent (P 0.05) the
GH response to ghrelin, making it similar to that of GHRH
alone but still higher (P 0.05) than that after GHRH during
CST or SS infusion (Tables 1 and 2 and Fig. 2).
The percentage inhibitory effects of CST and SS on the
FIG. 1. Mean (SEM) % GH variations vs. baseline dur-
ing infusion with CST-14 (2.0 g/kg/h iv), SS-14 (2.0
g/kg/h iv), or saline in normal subjects.
TABLE 1. Mean (SEM) baseline and peak, AUC, and AUC GH
responses to GHRH (1.0 g/kg iv) administration alone or during
infusion with CST-14 (2.0 g/kg/h iv) or SS-14 (2.0 g/kg/h iv) in
normal subjects
Baseline
(g/liter)
Peak
(g/liter)
AUC
(g/liter/h)
AUC
(g/liter/h)
GHRH 1.4  0.7 25.0  9.1 1511.1  456.2 1383.9  455.1
GHRHCST 0.1  0.1 4.1  0.8 291.0  37.1 289.2  82.3
GHRHSS 0.1  0.1 3.6  0.8 200.4  35.9 195.2  39.4
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mean GH response to ghrelin were similar (53% and 69%).
The mean percentage inhibitory effects of CST and SS on the
GH response to ghrelin were lower than those on the re-
sponse to GHRH but the difference did not attain statistical
significance.
The PRL, ACTH, and cortisol responses to ghrelin alone
were not significantly modified by either CST or SS admin-
istration (Table 2 and Fig. 3).
CST as well as SS also inhibited (P  0.01) basal insulin
secretion (407.7  131.3 and 654.5  152.8, respectively,
vs.50.4 46.6 mU/liter/h) (Fig. 4). The inhibitory effect of
CST and SS on insulin secretion was not modified by ghrelin
coadministration that when given alone was able per se to
significantly reduce insulin secretion (P  0.01), although to
an extent lower than that induced by SS (P  0.01) and CST
(P, NS) (Table 2 and Fig. 5).
CST and SS also induced a trend toward a transient re-
duction (P  0.05 at 45 min after CST only) of basal glucose
levels (964.4  723.1 and 417.0  819.6, respectively, vs.
14.1  270.4 mg/dl/h) (Fig. 4). On the other hand, ghrelin
induced an increase in glucose levels (P 0.05 from time15
min) that was not modified by either CST or SS infusion
(Table 2 and Fig. 5).
Side effects
A transient facial flushing was observed in two subjects
after administration of GHRH. Two subjects sensed a pecu-
liar sudden increase in appetite directly following ghrelin
administration. CST and SS administration elicited no side
effect.
Discussion
The results of the present study first show that CST-14
inhibits both basal and GHRH- or ghrelin-stimulated GH
secretion in humans to the same extent of SS-14. The GH-
releasing activity of ghrelin seems, however, partially resis-
tant to CST as well as to SS that do not modify the stimulatory
effect of ghrelin on both lactotroph and corticotroph secre-
tion. On the other hand, CST-14, like SS-14, displays an
inhibitory effect on insulin secretion. An inhibitory effect on
insulin secretion is recorded also after acute administration
of ghrelin that, however, does not modify that of CST and SS.
CST and SS do not modify the ghrelin-induced increase in
glucose levels.
CST-14 is a neuropeptide with a high structural homology
with SS-14 though encoded by distinct genes (1–3). CST-14
and CST-17 and -29 bind to all SS receptor subtypes with an
affinity (1–2 nm) quite close to that of SS (1, 3, 7). This evi-
dence predicted that CST possesses the classical SS activities
including regulation of both endocrine and exocrine secre-
tions, neurotransmission, neuromodulation, and inhibition
of tumor growth (5, 6).
Indeed, our present study shows that CST-14 displays the
classical effects of SS-14 (5, 6) inhibiting to the same extent
FIG. 2. Mean (SEM)GH responses to GHRH
(1.0 g/kg iv) or ghrelin (1.0 g/kg iv) admin-
istration alone or during infusion with CST-14
(2.0 g/kg/h iv) or SS-14 (2.0 g/kg/h iv) in nor-
mal subjects.
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both basal and GHRH- or ghrelin-stimulated GH secretion as
well as basal insulin secretion in humans. An inhibitory
action of CST-14 on GH secretion similar to that of SS-14 has
also been recently demonstrated by our group in dogs (33).
From the physiological point of view, it was probably more
appropriate to study the effects of the human CST-17 and -29
forms. However, the similar high affinity of CST-14, -17, and
-29 to SS receptors predicts that these molecular forms share
the same endocrine activity.
The observation that CST possesses central activities (such
as reduction of locomotor activity and induction of slow-
wave sleep) that are not shared by SS pointed to the existence
of specific receptors for CST distinct from those of SS (1,
8–10). This hypothesis has been recently supported by the
evidence that CST-14 and -17, but not SS-14, possess addi-
tional binding sites and bind to the GHS-R (Refs. 12 and 13;
our unpublished results). Notice that CST-14 and -17 displace
ghrelin and synthetic peptidyl GHSs from pituitary-binding
sites with a 50% inhibitory concentration value about 50-fold
higher than that required to inhibit the binding of radiola-
beled SS-to-SS receptors (Refs. 1, 7, 12, and 13; our unpub-
lished results). Thus, this evidence suggested the possibility
that CST, at variance with SS, has peculiar interaction on
ghrelin receptor and activity.
Like synthetic GHSs, ghrelin possesses potent stimula-
tory activity on somatotroph secretion (14, 18, 19, 26, 29,
34) but is able to also significantly stimulate PRL and
ACTH secretion (26, 29). Ghrelin also possesses other cen-
tral and peripheral actions including, for instance, stim-
ulation of food intake and influence on insulin secretion
FIG. 3. Mean (SEM) % PRL, ACTH,
and cortisol variations vs. baseline after
ghrelin (1.0 g/kg iv) administration
alone or during infusion with CST-14
(2.0 g/kg/h iv) or SS-14 (2.0 g/kg/h iv)
in normal subjects.
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and glucose metabolism (30 –32, 35). These actions are
mediated by the GHS-Rs that are mainly distributed
within the hypothalamus-pituitary unit but also in other
central and peripheral animal and human tissues (18 –24).
Regarding the GH-releasing activity, ghrelin has no in-
teraction with synthetic GHSs, synergizes with GHRH,
and seems partially refractory to the inhibitory effect of
exogenous SS (26 –28).
Our present findings show that either CST-14 or SS-14
almost abolishes the GH response to GHRH but only
blunts the stimulatory effect of ghrelin on GH secretion.
This suggests that ghrelin is partially refractory to the
inhibitory effect elicited by the activation of SS receptors
(1, 3, 7) in agreement with studies demonstrating that
GHSs act, at least partially, as functional SS antagonists at
both the pituitary and the hypothalamic level (18, 20, 36).
In fact, ghrelin and synthetic GHSs neither bind SS recep-
tors (12) nor decrease hypothalamic SS release (36, 37) but
are able to counteract the hyperpolarizing effect of SS on
the cell membrane (20, 36). The functional SS antagonism
exerted by GHSs likely explains their synergic effect with
GHRH (18, 20, 36).
Neither CST nor SS modified the lactotroph and cortico-
troph responsiveness to ghrelin, in agreement with previous
studies showing that SS does not influence lactotroph and
corticotroph responses to synthetic GHS (38). In agreement
with in vitro studies, evidence that CST and SS do not affect
the ghrelin-induced PRL increase is against the hypothesis
that GHS action on lactotroph secretion takes place directly
at the pituitary level (18, 39). On the other hand, the stim-
ulatory effect of ghrelin on the hypothalamus-pituitary-
adrenal axis is totally mediated by central actions that could
include CRH- and vasopressin-mediated mechanisms but
also other neurotransmitters such as NPY and -aminobu-
tyric acid(18). Again, evidence that CST and SS do not affect
the ghrelin-induced hypothalamus-pituitary-adrenal axis re-
sponse agrees with a central nervous system-mediated action
of ghrelin (18).
As anticipated, CST-14, like SS-14, infusion clearly inhib-
ited insulin secretion which, though to a lower extent, was
decreased also by the acute administration of ghrelin, in
agreement with previous observation (30). Interestingly, gh-
relin administration during CST or SS infusion did not mod-
ify its inhibitory action on insulin levels; these findings
suggest that the negative influence of acute ghrelin admin-
istration on -cell secretion would be mediated by enhanced
somatostatinergic activity. Indeed, at least at the hypotha-
lamic level, increased SS release has been reported after ex-
posure to ghrelin in rats (37).
The present study confirms that the acute administra-
tion of ghrelin is followed by rise in glucose levels and
shows that this administration is not abolished by CST or
SS infusion. The hyperglycemic effect recorded after acute
ghrelin administration is unlikely explained by a decrease
in insulin levels that seems to occur later (30) and an
increase in glucagon secretion that per se should increase
insulin secretion (40). The hyperglycemic effect of ghrelin
would reflect direct, non-GH-mediated action at the he-
patic level (41).
The mechanisms underlying the influence of ghrelin on
FIG. 4. Mean (SEM) % insulin and glu-
cose variations vs. baseline during infusion
with CST-14 (2.0 g/kg/h iv) or SS-14 (2.0
g/kg/h iv) or after acute ghrelin (1.0 g/kg
iv) administration in normal subjects.
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glucose metabolism and insulin secretion are, however, not
surprising because it is expressed in the gut as well as in the
pancreatic  cells (15, 31, 32, 42) and counteracts insulin
action in hepatoma cell lines (41). Moreover, ghrelin mod-
ulates food intake and energy expenditure, and ghrelin con-
centration is increased by fasting and reduced by glucose
load in rats (31, 32). Moreover, prolonged treatment with
synthetic GHSs was often coupled with hyperglycemia in
healthy elderly subjects (43). The understanding of the in-
fluence of ghrelin on the endocrine pancreas and glucose
metabolism and its interplay with SS/CST requires further
studies that are ongoing.
In conclusion, this study primarily shows that CST-14 is
as effective as SS-14 in inhibiting both basal and GHRH-
or ghrelin-stimulated GH release and insulin secretion in
healthy normal individuals. This evidence indicates that
these actions reflect classical activation of SS receptors that
are bound by CST with an affinity similar to that of SS. The
TABLE 2. Mean (SEM) basal and peak (or nadir, for insulin, only), AUC, and AUC GH, PRL, ACTH, cortisol, insulin, and glucose
responses to ghrelin (1.0 g/kg iv) administration alone or during infusion with CST-14 (2.0 g/kg/h iv) or SS-14 (2.0 g/kg/h iv) in
normal subjects
Ghrelin Ghrelin  CST
Baseline Peak (or nadira) AUC AUC Baseline
GH 1.3  1.1 91.5  16.7 5300.7  922.9 5150.3  917.9 0.1  0.1
Prolactin 6.7  0.7 14.4  2.1 1021.8  102.8 422.7  142.8 5.7  0.7
ACTH 25.1  3.4 85.0  20.9 3979.2  897.2 1716.3  812.3 18.5  2.7
Cortisol 112.4  18.0 175.9  13.7 13097.4  1456.2 2985.2  893.1 81.8  5.4
Insulin 11.9  1.1 8.5  0.6a 857.1  58.5 212.6  43.3 7.7  1.2
Glucose 93.6  8.4 109.4  9.3 9293.6  705.7 1086.4  426.0 72.8  5.7
See text for units of measure.
a Nadir.
FIG. 5. Mean (SEM)  insulin and glucose
responses to ghrelin (1.0 g/kg iv) admin-
istration alone or during infusion with
CST-14 (2.0 g/kg/h iv) or SS-14 (2.0 g/
kg/h iv) in normal subjects.
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activation of SS receptors likely masks the ability of CST-
14, but not of SS-14, to also bind the GHS-R with high
affinity and thus to show some peculiar interaction with
ghrelin receptor and activity. To clarify the impact, if any,
of CST on ghrelin system, we are currently studying the
effects of a CST analog that does not show any binding
affinity to SS receptors but maintains its ability to bind the
GHS-R.
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